OTTAWA, Sept. 27 /CNW/ - Liponex Inc. (TSX:LPX), a biopharmaceutical company specializing in developing advanced products related to High Density Lipoprotein (HDL), often called “good cholesterol,” announced today that the company will present a CRD5 development update at the 16th International Symposium for Drugs Affecting Lipid Metabolism (DALM). Dr. Daniel Sparks, founder and Chief Scientific Officer of Liponex, will give the presentation entitled, “Clinical Development of a Novel HDL Therapeutic” on October 5, 2007 in New York City.
